| 74.73 Delayed Data As of Apr 24 |  +0.13 / +0.17%Today’s Change | 56.26 Today|||52-Week Range 83.85 | -2.20% Year-to-Date |
| Previous close | 74.60 |
| Today’s open | 74.73 |
| Day’s range | 73.98 - 75.11 |
| Volume | 12,193,763 |
| Average volume (3 months) | 12,114,351 |
| Market cap | $189.1B |
| Earnings growth (last year) | +165.32% |
| Earnings growth (this year) | +7.87% |
| Earnings growth (next 5 years) | +9.20% |
| Revenue growth (last year) | +6.17% |
| P/E ratio | 32.2 |
| Price/Sales | 4.82 |
| Price/Book | 7.11 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +1.92 | +2.53% |
| PFEPfizer | -0.05 | -0.13% |
| ABTAbbott Laboratories | +0.65 | +0.85% |
| LLYEli Lilly and Co | +0.51 | +0.43% |
| Next reporting date | April 30, 2019 |
| EPS forecast (this quarter) | $1.06 |
| Annual revenue (last year) | $42.4B |
| Annual profit (last year) | $6.2B |
| Net profit margin | 14.65% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer Kenneth C. Frazier |
CFO & Executive Vice President-Global Services Robert M. Davis |
Corporate headquarters Kenilworth, New Jersey |
